NCT06814132View on ClinicalTrials.gov

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

October 4, 2025

Study Completion Date

October 14, 2025

Conditions
Kidney Failure, ChronicEnd-Stage Kidney DiseaseRenal Failure, ChronicRenal Failure, End-StageHealthy Participants
Interventions
DRUG

MK-5684

Oral tablet

DRUG

Prednisone

Oral tablet

DRUG

Fludrocortisone acetate

Oral tablet

Trial Locations (2)

32809

Orlando Clinical Research Center ( Site 0002), Orlando

60643

Research by Design ( Site 0001), Chicago

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY